A

Amgen

Makes biotech medicines for serious illnesses

Field Reimbursement Manager

Full-TimePosted on 10/26/2026
$145.5k - $196.8k/yr
Mid
Bachelor's, Master's, PhD, Associate's
Anaheim, CA, USA
HybridRemote work from home with one to two home-office days weekly; two days weekly in the territory for appointments; travel up to 40%.
Customer Experience & SupportCustomer Success
H1B Sponsorship Available

About the job

Requirements
  • A doctorate, or a master's degree and 3 years of customer service and/or leadership experience, or a bachelor's degree and 5 years of customer service and/or leadership experience, or an associate's degree and 10 years of customer service and/or leadership experience, or a high school diploma/GED and 12 years of customer service and/or leadership experience.
  • Experience directly managing people and/or leadership experience leading teams, projects, programs, or directing resource allocation; this experience may run concurrently with the required technical experience.
  • At least two years of experience in public or private third-party access or the pharmaceutical industry in managed care, clinical support, and/or sales.
  • Strong medical reimbursement experience and/or knowledge of specialty pharmacy and buy-and-bill processes.
  • Presentation and facilitation skills.
  • Strong written and oral communication skills.
  • Organizational skills and project management experience, including managing multiple projects.
  • Computer literacy, including Microsoft Word, Excel, and PowerPoint, and the ability to conduct web-based meetings.
  • Healthcare industry experience, including insurance verification, claim adjudication, physician offices or clinics, pharmacies, and/or pharmaceutical manufacturers.
  • Experience working with hubs and in-depth knowledge of billing, coding, and appeals issues across physician types.
  • Ability to collaborate and lead cross-functional partner meetings.
  • Experience with commercial payers, Medicare plans, and state Medicaid in a geographic region.
  • Must live in the geography or within 10 miles of the geography border.
Responsibilities
  • Manage defined accounts within a specified geographic region for Patient Access and Reimbursement.
  • Support products by executing the collaborative territory strategic plan.
  • Ensure understanding of the reimbursement process, field reimbursement services, and patient support programs.
  • Resolve patient-level reimbursement issues, using knowledge and experience with patient health information.
  • Act as an extension of the HUB, providing live one-on-one coverage support.
  • Assist from physician order through reimbursement, including payer prior authorization and appeals or denials requirements and forms.
  • Review patient-specific information when a site requests assistance resolving issues or coverage challenges.
  • Educate and update healthcare providers on private and public payer coverage and changes that affect patient product access.
  • Coordinate access and reimbursement issues with relevant partners, including the HUB.
  • Explain to healthcare providers how products are covered under commercial, Medicare, and Medicaid benefits.
  • Serve as a payer expert for the defined geography and promptly communicate payer changes to stakeholders.
  • Educate offices during the access process on formulary coverage and utilization-management criteria, insurance forms and procedures, benefits investigation, prior authorization, appeals, and claims resolution.
  • Educate offices using approved materials.
  • Review patient insurance benefit options and alternate funding or financial assistance programs.
  • Collaborate with other departments to resolve reimbursement issues.
Desired Qualifications
  • Bachelor's degree in business, healthcare, or a related field.
  • Six years of experience with specialty or biologic self-injectable products under the pharmacy benefit, or physician-administered products under the buy-and-bill/medical benefit.
  • Advanced knowledge of medical insurance terminology.
  • Knowledge of Centers for Medicare & Medicaid Services policies and processes, with expertise in Medicare Part B for buy-and-bill products and Part D for pharmacy products.
  • Ability to manage ambiguity and solve problems.
  • Ability to manage expenses within allocated budgets.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.